Oxygenation of the Endocannabinoid, 2-Arachidonylglycerol, to Glyceryl Prostaglandins by Cyclooxygenase-2*

Cyclooxygenases (COX) play an important role in lipid signaling by oxygenating arachidonic acid to endoperoxide precursors of prostaglandins and thromboxane. Two cyclooxygenases exist which differ in tissue distribution and regulation but otherwise carry out identical chemical functions. The neutral arachidonate derivative, 2-arachidonylglycerol (2-AG), is one of two described endocannabinoids and appears to be a ligand for both the central (CB1) and peripheral (CB2) cannabinoid receptors. Here we report that 2-AG is a substrate for COX-2 and that it is metabolized as effectively as arachidonic acid. COX-2-mediated 2-AG oxygenation provides the novel lipid, prostaglandin H2 glycerol ester (PGH2-G), in vitro and in cultured macrophages. PGH2-G produced by macrophages is a substrate for cellular PGD synthase, affording PGD2-G. Pharmacological studies reveal that macrophage production of PGD2-G from endogenous sources of 2-AG is calcium-dependent and mediated by diacylglycerol lipase and COX-2. These results identify a distinct function for COX-2 in endocannabinoid metabolism and in the generation of a new family of prostaglandins derived from diacylglycerol and 2-AG.

[1]  Lawrence J. Marnett,et al.  Structural insights into the stereochemistry of the cyclooxygenase reaction , 2000, Nature.

[2]  B. Yagen,et al.  Oxidative metabolism of anandamide. , 2000, Prostaglandins & other lipid mediators.

[3]  L. Marnett,et al.  Spatial Requirements for 15-(R)-Hydroxy-5Z,8Z,11Z,13E-eicosatetraenoic Acid Synthesis within the Cyclooxygenase Active Site of Murine COX-2 , 2000, The Journal of Biological Chemistry.

[4]  S. Ghosh,et al.  Transcriptional Activation of the Cyclooxygenase-2 Gene in Endotoxin-treated RAW 264.7 Macrophages* , 2000, The Journal of Biological Chemistry.

[5]  L. Marnett,et al.  Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[6]  K. Waku,et al.  Evidence That 2-Arachidonoylglycerol but Not N-Palmitoylethanolamine or Anandamide Is the Physiological Ligand for the Cannabinoid CB2 Receptor , 2000, The Journal of Biological Chemistry.

[7]  L. Petrocellis,et al.  Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. , 1999, European journal of biochemistry.

[8]  L. Marnett,et al.  The Binding of Arachidonic Acid in the Cyclooxygenase Active Site of Mouse Prostaglandin Endoperoxide Synthase-2 (COX-2) , 1999, The Journal of Biological Chemistry.

[9]  L. Petrocellis,et al.  Cannabimimetic fatty acid derivatives: the anandamide family and other endocannabinoids. , 1999, Current medicinal chemistry.

[10]  L. Petrocellis,et al.  Phosphatidic Acid as the Biosynthetic Precursor of the Endocannabinoid 2‐Arachidonoylglycerol in Intact Mouse Neuroblastoma Cells Stimulated with Ionomycin , 1999, Journal of neurochemistry.

[11]  K. Waku,et al.  Evidence That the Cannabinoid CB1 Receptor Is a 2-Arachidonoylglycerol Receptor , 1999, The Journal of Biological Chemistry.

[12]  L. Marnett,et al.  Covalent modification of cyclooxygenase-2 (COX-2) by 2-acetoxyphenyl alkyl sulfides, a new class of selective COX-2 inactivators. , 1998, Journal of medicinal chemistry.

[13]  P. Lipsky,et al.  Cyclooxygenase in biology and disease , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[14]  D. Swinney,et al.  The Dynamics of Prostaglandin H Synthases , 1998, The Journal of Biological Chemistry.

[15]  C. Bayly,et al.  The interaction of arginine 106 of human prostaglandin G/H synthase-2 with inhibitors is not a universal component of inhibition mediated by nonsteroidal anti-inflammatory drugs. , 1997, Molecular pharmacology.

[16]  C. Ramesha,et al.  Synthesis of Prostaglandin E2 Ethanolamide from Anandamide by Cyclooxygenase-2* , 1997, The Journal of Biological Chemistry.

[17]  D. Piomelli,et al.  A second endogenous cannabinoid that modulates long-term potentiation , 1997, Nature.

[18]  L. Petrocellis,et al.  Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells. , 1997, The Biochemical journal.

[19]  William L. Smith,et al.  Prostaglandin Endoperoxide H Synthases (Cyclooxygenases)-1 and −2* , 1996, The Journal of Biological Chemistry.

[20]  J. Morrow,et al.  Peroxynitrite, the coupling product of nitric oxide and superoxide, activates prostaglandin biosynthesis. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[21]  J. Chow,et al.  Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2 , 1996, Nature Structural Biology.

[22]  R. Jacobs,et al.  Biosynthesis of arachidonic acid metabolites in Limulus polyphemus amebocytes: analysis by liquid chromatography-electrospray ionization mass spectrometry , 1996 .

[23]  Ke-He Ruan,et al.  Role of Val509 in Time-dependent Inhibition of Human Prostaglandin H Synthase-2 Cyclooxygenase Activity by Isoform-selective Agents* , 1996, The Journal of Biological Chemistry.

[24]  Y. Jeon,et al.  Attenuation of inducible nitric oxide synthase gene expression by delta 9-tetrahydrocannabinol is mediated through the inhibition of nuclear factor- kappa B/Rel activation. , 1996, Molecular pharmacology.

[25]  J. Gierse,et al.  A Single Amino Acid Difference between Cyclooxygenase-1 (COX-1) and −2 (COX-2) Reverses the Selectivity of COX-2 Specific Inhibitors* , 1996, The Journal of Biological Chemistry.

[26]  William L. Smith,et al.  Involvement of Arginine 120, Glutamate 524, and Tyrosine 355 in the Binding of Arachidonate and 2-Phenylpropionic Acid Inhibitors to the Cyclooxygenase Active Site of Ovine Prostaglandin Endoperoxide H Synthase-1 (*) , 1996, The Journal of Biological Chemistry.

[27]  H. Herschman.  Prostaglandin synthase 2. , 1996, Biochimica et biophysica acta.

[28]  Z. Vogel,et al.  Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. , 1995, Biochemical pharmacology.

[29]  K. Rice,et al.  Cannabinoid receptor binding and agonist activity of amides and esters of arachidonic acid. , 1994, Molecular pharmacology.

[30]  K. Seibert,et al.  Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[31]  J. Vane,et al.  Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[32]  W. Xie,et al.  Prostaglandin G/H synthase isoenzyme 2 expression in fibroblasts: regulation by dexamethasone, mitogens, and oncogenes. , 1993, Archives of biochemistry and biophysics.

[33]  D. Gibson,et al.  Isolation and structure of a brain constituent that binds to the cannabinoid receptor. , 1992, Science.

[34]  T. Shimokawa,et al.  Tyrosine 385 of prostaglandin endoperoxide synthase is required for cyclooxygenase catalysis. , 1990, The Journal of biological chemistry.

[35]  F. Fitzpatrick,et al.  Selective inhibition of receptor-coupled phospholipase C-dependent processes in human platelets and polymorphonuclear neutrophils. , 1990, The Journal of pharmacology and experimental therapeutics.

[36]  L. Marnett,et al.  Mechanism of the stimulation of prostaglandin H synthase and prostacyclin synthase by the antithrombotic and antimetastatic agent, nafazatrom. , 1984, Molecular pharmacology.

[37]  D. Amin,et al.  Relative activities of rat and dog platelet phospholipase A2 and diglyceride lipase. Selective inhibition of diglyceride lipase by RHC 80267. , 1982, The Journal of biological chemistry.

[38]  L. Marnett,et al.  Nonenzymatic reduction of prostaglandin H by lipoic acid. , 1977, Biochemistry.

[39]  M. Hamberg,et al.  Detection and isolation of an endoperoxide intermediate in prostaglandin biosynthesis. , 1973, Proceedings of the National Academy of Sciences of the United States of America.

[40]  J. Vane,et al.  Cyclooxygenases 1 and 2. , 1998, Annual review of pharmacology and toxicology.

[41]  M. Glass,et al.  Cannabinoid receptors and their endogenous agonists. , 1998, Annual review of pharmacology and toxicology.

[42]  R. Kurumbail,et al.  Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents , 1996, Nature.

[43]  L. Marnett,et al.  Preparation and proteolytic cleavage of apoprostaglandin endoperoxide synthase. , 1990, Methods in enzymology.